Iron Mountain Reiterates Guidance

Iron Mountain affirmed full year 2024 guidance; details are summarized in the table below.2024 Guidance(1)($ in millions, except per share data)   2024 Guidance Y/Y % Changeat MidpointTotal

Iron Mountain affirmed full year 2024 guidance; details are summarized in the table below.

2024 Guidance(1)
($ in millions, except per share data)    
  2024 Guidance  

Y/Y % Change

at Midpoint

Total Revenue $6,000 – $6,150   11%
Adjusted EBITDA $2,175 – $2,225   12%
AFFO $1,300 – $1,335   9%
AFFO Per Share $4.39 – $4.51   8%
Total
0
Shares
Related Posts
Read More

Seagen Highlights First Solid Tumor Data For An ADCETRIS Immunotherapy Combination And Preclinical Data For Novel CD30-Directed Antibody-Drug Conjugate At Society For Immunotherapy Of Cancer Annual Meeting

– Initial Phase 2 data presented for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma –– Preclinical data presented for novel

SGEN